Pharma BD Deal Intelligence
Merck paid $700M upfront, up to $1.3B total, for Curon's CN201, a CD3xCD19 bispecific T-cell engager in Phase 1 for relapsed/refractory non-Hodgkin lymphoma and Phase 1b/2 for B-ALL, with a pre-tax charge of ~$750M booked at close—though the drug's autoimmune potential remains unproven beyond the deal's stated indications.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Merck is paying $700 million upfront and up to $600 million in milestones to acquire global rights to CN201, a CD19xCD3 bispecific T-cell engager, from China's…
Merck is acquiring global rights to CN201, a CD19xCD3 bispecific antibody, from Shanghai-based Curon Biopharmaceutical for $700 million upfront and up to…
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical (October 1, 2024).
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Merck entered a definitive agreement to acquire global rights to CN201 from Curon Biopharmaceutical for $700M upfront plus up to $600M in milestones contingent on development and regulatory approval. The acquisition was completed on October 1, 2024 (Merck recorded a pre-tax charge of ~$750M reflecting the upfront payment and related costs). CN201 is a CD3xCD19 bispecific T-cell engager in Phase 1 for r/r NHL and Phase 1b/2 for r/r B-ALL, with potential in B-cell autoimmune diseases. Top-25 pharma buyer.
90K US cases/yr · $25.0B Global B-cell NHL and Autoimmune Therapeutics Market
CN201 (MK-2006 following acquisition) is a CD3xCD19 bispecific T-cell-engager antibody developed for two core areas. Relapsed/refractory non-Hodgkin lymphoma (NHL) encompasses a heterogeneous group of B-cell malignancies with ~80,000 new US diagnoses annually; diffuse large B-cell lymphoma (DLBCL, ~40% of NHL), follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma remain the major subtypes. Despite the CAR-T revolution (Yescarta, Kymriah, Breyanzi) and CD20xCD3 bispecifics (Lunsumio, Columvi, Epkinly), a meaningful fraction of r/r patients relapse, and access constraints limit CAR-T utilization. Relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) affects ~3,000 US patients annually with poor salvage outcomes absent HSCT; approved therapies include Blincyto (blinatumomab CD19xCD3), Besponsa (inotuzumab ozogamicin CD22 ADC), and CAR-Ts Tecartus and Kymriah. The autoimmune opportunity spans systemic lupus erythematosus (~200,000), multiple sclerosis (~1 million), myasthenia gravis, rheumatoid arthritis, and ANCA-associated vasculitis, where deep B-cell depletion is emerging as a potentially curative-intent intervention following early CAR-T and bispecific antibody case reports demonstrating drug-free remission after autoreactive B-cell resetting.
The B-cell depletion landscape is highly competitive across modalities. CD20-directed monoclonal antibodies: Rituxan (rituximab, Roche), Gazyva (obinutuzumab, Roche), Arzerra (ofatumumab, Novartis), and Kesimpta (ofatumumab SC, Novartis) for multiple sclerosis. CD19xCD3 T-cell engagers: Blincyto (blinatumomab, Amgen, approved for B-ALL and r/r DLBCL), with CN201 (MK-2006) as the leading clinical CD19xCD3 Phase 1 competitor. CD20xCD3 T-cell engagers: Lunsumio (mosunetuzumab, Roche), Columvi (glofitamab, Roche), Epkinly (epcoritamab, AbbVie/Genmab), and odronextamab (Regeneron, CRL received 2024). CD19 CAR-T cellular therapies: Yescarta and Tecartus (axicabtagene and brexucabtagene ciloleucel, Gilead/Kite), Kymriah (tisagenlecleucel, Novartis), Breyanzi (lisocabtagene maraleucel, Bristol Myers Squibb). CD22 ADC: Besponsa (inotuzumab ozogamicin, Pfizer), and Lonca (loncastuximab tesirine, Swedish Orphan Biovitrum). Autoimmune CD19 CAR-T in development: Cabaletta (CABA-201), Kyverna (KYV-101), Gracell (GC012F, acquired by AstraZeneca), Novartis YTB323, and Bristol Myers/2seventy. Ianalumab (Novartis anti-BAFF-R) and obinutuzumab (Gazyva) expansions target autoimmune B-cell depletion. The class convergence across oncology and autoimmunity is driving major pharma deal activity.
Merck closed the acquisition of global rights to CN201 on October 1, 2024, paying $700M upfront (pre-tax charge ~$750M incl. related costs) with up to $600M in development/regulatory milestones.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Curon Biopharmaceutical (Shanghai) Co. Ltd. (this deal) | 2024 | $1.3B | — |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2024 deals · Merck & Co. Inc. deals · Hematology deals